Christopher Cleon Rowe

Christopher Cleon Rowe's AcademicInfluence.com Rankings

Medical

#1844

World Rank

#2222

Historical Rank

Neurology

#171

World Rank

#240

Historical Rank

medical Degrees

Christopher Cleon Rowe

Biology

#7327

World Rank

#10230

Historical Rank

Neuroscience

#932

World Rank

#971

Historical Rank

biology Degrees

Download Badge

Medical
Biology

Christopher Cleon Rowe's Degrees

PhD Neuroscience Stanford University

Why Is Christopher Cleon Rowe Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Christopher Cleon Rowe's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) (5616)
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018) (4523)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria (2014) (2513)
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study (2013) (1546)
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria (2016) (1163)
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. (2015) (1112)
High performance plasma amyloid-β biomarkers for Alzheimer’s disease (2018) (969)
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging (2010) (950)
Alzheimer's disease (2015) (796)
β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease (2007) (719)
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease (2011) (718)
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease (2009) (680)
Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism (2008) (634)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup (2011) (624)
Imaging β-amyloid burden in aging and dementia (2007) (610)
The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET (2015) (536)
Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. (2015) (476)
Tau imaging: early progress and future directions (2015) (435)
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. (2007) (409)
Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography (2008) (401)
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study (2015) (374)
Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association (2013) (364)
Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association (2013) (362)
Blood-based protein biomarkers for diagnosis of Alzheimer disease. (2012) (354)
Relationship between atrophy and β‐amyloid deposition in Alzheimer disease (2010) (354)
Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease (2013) (318)
Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging. (2011) (304)
Intensity of dementia through latent variable modelling (I-DeLV) in the AIBL cohort (2012) (290)
Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment (2014) (289)
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. (2011) (280)
Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin (2013) (278)
Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias (2011) (278)
Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease (2008) (272)
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions (2018) (266)
Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease (2007) (255)
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. (2012) (244)
Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease (2013) (235)
β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia (2010) (232)
Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. (2014) (228)
SPECT brain imaging in epilepsy: a meta-analysis. (1998) (226)
Patterns of postictal cerebral blood flow in temporal lobe epilepsy (1991) (220)
The 18F-FDG PET Cingulate Island Sign and Comparison to 123I-β-CIT SPECT for Diagnosis of Dementia with Lewy Bodies (2009) (214)
Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing (2013) (207)
SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0* (2012) (207)
SPECT in the localisation of extratemporal and temporal seizure foci. (1995) (205)
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group (2021) (204)
Inflammation following stroke (2006) (199)
Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (2013) (198)
Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations (2013) (198)
High performance plasma amyloid-beta biomarkers for Alzheimer's disease (2018) (197)
Brain Amyloid Imaging (2011) (191)
Cerebral quantitative susceptibility mapping predicts amyloid-&bgr;-related cognitive decline (2017) (185)
Postictal switch in blood flow distribution and temporal lobe seizures. (1992) (183)
Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. (2014) (183)
Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study (2016) (182)
Fibre-specific white matter reductions in Alzheimer’s disease and mild cognitive impairment (2018) (177)
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease (2012) (175)
Imaging markers for Alzheimer disease (2013) (174)
In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease (2014) (167)
Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition (2012) (163)
High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. (2009) (163)
Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. (2013) (162)
In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies (2007) (159)
Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study (2011) (153)
Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. (2015) (151)
Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education (2013) (148)
Adherence to a Mediterranean diet and Alzheimer's disease risk in an Australian population (2012) (147)
Impaired default network functional connectivity in autosomal dominant Alzheimer disease (2013) (146)
Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. (2011) (142)
Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts (2018) (140)
Larger temporal volume in elderly with high versus low beta-amyloid deposition. (2010) (140)
Head-to-Head Comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-Amyloid Imaging in Aging and Dementia (2013) (138)
Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age (2013) (136)
Visual and quantitative analysis of interictal SPECT with technetium-99m-HMPAO in temporal lobe epilepsy. (1991) (132)
Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. (2010) (125)
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer’s disease (2019) (123)
Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease (2014) (121)
Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease (2016) (121)
Incidence of cerebral microbleeds in preclinical Alzheimer disease (2014) (120)
Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology (2018) (118)
In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133 (2010) (116)
Beta-amyloid imaging with florbetaben (2015) (116)
Association of Cerebral Amyloid-&bgr; Aggregation With Cognitive Functioning in Persons Without Dementia (2018) (116)
Intense physical activity is associated with cognitive performance in the elderly (2012) (115)
Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (2012) (114)
APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease (2014) (113)
Effects of Anticholinergic Drugs on Cognitive Function in Older Australians: Results from the AIBL Study (2011) (112)
Dietary patterns and cognitive decline in an Australian study of ageing (2014) (110)
A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study (2014) (110)
Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults (2012) (109)
Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia (2018) (107)
Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias (2009) (106)
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease (2013) (105)
The Relationship between Sleep Quality and Brain Amyloid Burden. (2016) (100)
Ictal SPECT using technetium-99m-HMPAO: methods for rapid preparation and optimal deployment of tracer during spontaneous seizures. (1993) (100)
Implementation and Validation of an Adaptive Template Registration Method for 18F-Flutemetamol Imaging Data (2013) (99)
Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease (2014) (98)
The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias (2008) (97)
Comparison of MR-less PiB SUVR quantification methods (2015) (97)
Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer’s Disease: A Preliminary Study (2014) (93)
Positron emission tomography and epilepsy. (2002) (93)
Biochemically-defined pools of amyloid-&bgr; in sporadic Alzheimer’s disease: correlation with amyloid PET (2017) (91)
Aβ-amyloid and Tau Imaging in Dementia. (2017) (90)
Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). (2013) (88)
Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. (2011) (88)
Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. (2007) (86)
Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study (2014) (86)
Risk prediction of late-onset Alzheimer’s disease implies an oligogenic architecture (2020) (86)
In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. (2009) (85)
Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale (2018) (82)
Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging (2008) (80)
Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease (2014) (79)
Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies (2018) (79)
In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106 (2013) (77)
18F-Florbetaben PET beta-amyloid binding expressed in Centiloids (2017) (77)
Blood-Borne Amyloid-β Dimer Correlates with Clinical Markers of Alzheimer's Disease (2010) (76)
Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease (2014) (76)
Radiation Dosimetry of β-Amyloid Tracers 11C-PiB and 18F-BAY94-9172 (2009) (76)
Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. (2014) (76)
Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (2015) (75)
Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL (2018) (74)
Radioiodinated clioquinol as a biomarker for β‐amyloid: Zn2+ complexes in Alzheimer's disease (2006) (74)
Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry (2017) (74)
Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies (2014) (74)
Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study (2016) (73)
Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score (2015) (72)
Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden (2018) (72)
An increased neutrophil–lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation (2014) (67)
APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease (2015) (67)
Update on Appropriate Use Criteria for Amyloid PET Imaging: Dementia Experts, Mild Cognitive Impairment, and Education (2013) (67)
Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale (2016) (66)
Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease (2013) (66)
Olfactory deficits and amyloid-β burden in Alzheimer's disease, mild cognitive impairment, and healthy aging: a PiB PET study. (2011) (64)
Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 2013;36:2981–2987 (2013) (64)
Association of Plasma Aß Peptides with Blood Pressure in the Elderly (2011) (63)
Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. (2016) (63)
Association of &bgr;-Amyloid and Apolipoprotein E &egr;4 With Memory Decline in Preclinical Alzheimer Disease (2018) (61)
Brain amyloid imaging. (2013) (61)
Influence of BDNF Val66Met on the relationship between physical activity and brain volume (2014) (60)
A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease (2019) (59)
Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. (2014) (59)
Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease (2019) (57)
Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative (2010) (57)
Awareness of olfactory deficits in healthy aging, amnestic mild cognitive impairment and Alzheimer's disease (2011) (57)
Amyloid burden and incident depressive symptoms in cognitively normal older adults (2017) (55)
Quantitative gait analysis in patients with dementia with Lewy bodies and Alzheimer's disease. (2007) (55)
Amyloid imaging with PET in early Alzheimer disease diagnosis. (2013) (55)
A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study (2017) (54)
Rapid decline in episodic memory in healthy older adults with high amyloid-β. (2013) (53)
Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease (2005) (53)
Assessment of the role of FDG PET in the diagnosis and management of children with refractory epilepsy (2005) (52)
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease (2012) (52)
18F-florbetaben Aβ imaging in mild cognitive impairment (2013) (52)
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease (2017) (52)
Aβ amyloid, cognition, and APOE genotype in healthy older adults (2013) (52)
MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET (2014) (51)
In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer. (2012) (50)
Plasma Cortisol, Brain Amyloid-β, and Cognitive Decline in Preclinical Alzheimer's Disease: A 6-Year Prospective Cohort Study. (2017) (49)
Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer's disease. (2011) (49)
Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. (2015) (48)
Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. (2013) (47)
Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods (2018) (47)
Relationship between Memory Performance and β-Amyloid Deposition at Different Stages of Alzheimer’s Disease (2012) (46)
18 F-THK 523 : a novel in vivo tau imaging ligand for Alzheimer ’ s disease (2011) (46)
The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update (2015) (46)
Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials (2013) (46)
Clinical Profile of PiB-Positive Corticobasal Syndrome (2013) (45)
Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial (2012) (45)
Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer’s disease (2020) (45)
Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Aβ accumulation in cognitively normal older adults and adults with MCI. (2015) (44)
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET. (2005) (43)
Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults (2017) (43)
Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using F-THK5105 PET (2014) (43)
Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing (2011) (42)
Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden. (2015) (42)
Decline in cognitive function over 18 months in healthy older adults with high amyloid-β. (2013) (42)
Alzheimer's Disease and the Early Signs of Age-Related Macular Degeneration. (2016) (41)
Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer’s disease (2020) (41)
Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease. (2015) (41)
Differential Diagnosis in Alzheimer’s Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid Imaging (2012) (41)
Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease (2020) (41)
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes (2017) (40)
Mediterranean diet adherence and rate of cerebral Aβ-amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (2018) (40)
Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. (2014) (40)
Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease (2021) (39)
Risk of Alzheimer's Disease in Obstructive Sleep Apnea Syndrome: Amyloid-β and Tau Imaging. (2018) (39)
b -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease (2007) (39)
Episodic memory decline predicts cortical amyloid status in community-dwelling older adults. (2011) (38)
A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer’s Disease (2016) (37)
Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology (2019) (37)
Ictal postictal and interictal single-photon emission tomography in the lateralization of temporal lobe epilepsy (1994) (37)
Amyloid-Related Memory Decline in Preclinical Alzheimer’s Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months (2015) (36)
Subacute Ischemic Stroke Is Associated With Focal 11C PiB Positron Emission Tomography Retention But Not With Global Neocortical A&bgr; Deposition (2012) (36)
Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) (2013) (36)
In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease. (2011) (36)
Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests. (2012) (36)
Differentiating the frontal presentation of Alzheimer's disease with FDG-PET. (2015) (36)
Non-Verbal Episodic Memory Deficits in Primary Progressive Aphasias are Highly Predictive of Underlying Amyloid Pathology. (2016) (35)
Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease. (2013) (34)
Computer-aided detection of cerebral microbleeds in susceptibility-weighted imaging (2015) (34)
Long night's journey into the day: amyloid-β imaging in Alzheimer's disease. (2012) (34)
Olfactory performance in AD, aMCI, and healthy ageing: a unirhinal approach. (2010) (34)
OPTIMAL REFERENCE REGION TO MEASURE LONGITUDINAL AMYLOID-BETA CHANGE WITH 18F-FLORBETABEN PET (2016) (34)
Cerebral β‐amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator‐related hemorrhage (2010) (33)
Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. (2017) (32)
Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging (2015) (32)
Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. (2015) (31)
Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study (2014) (30)
Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial (2020) (29)
Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort (2017) (29)
Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β: prodromal Alzheimer's disease? (2013) (29)
Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment. (2015) (29)
KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden (2018) (29)
Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease (2020) (28)
Human dosimetry and biodistribution of iodine-123-iododexetimide: a SPECT imaging agent for cholinergic muscarinic neuroreceptors. (1995) (28)
Predicting Alzheimer disease from a blood-based biomarker profile (2016) (28)
Amyloid Imaging in Alzheimer’s Disease and Other Dementias (2009) (28)
The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI (2013) (28)
Memory profiling with paired associate learning in Alzheimer's disease, mild cognitive impairment, and healthy aging. (2008) (27)
Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study (2017) (27)
Metabolic patterns and seizure outcomes following anterior temporal lobectomy (2019) (26)
Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-β. (2018) (26)
Automated (11)C-PiB standardized uptake value ratio. (2008) (25)
Fluoro-2-Deoxy-D-Glucose (FDG)-PET in APOEε4 Carriers in the Australian Population (2008) (25)
Efficient machine learning framework for computer-aided detection of cerebral microbleeds using the Radon transform (2014) (25)
Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. (2018) (25)
Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals (2020) (25)
Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness (2017) (24)
Amyloid-β: the seeds of darkness. (2011) (24)
Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. (2018) (24)
18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias (2015) (23)
Positron Emission Tomographic Imaging in Stroke (2015) (23)
RETINAL AMYLOID FLUORESCENCE IMAGING PREDICTS CEREBRAL AMYLOID BURDEN AND ALZHEIMER'S DISEASE (2014) (23)
Associations of neighborhood environment with brain imaging outcomes in the Australian Imaging, Biomarkers and Lifestyle cohort (2017) (23)
MR-Less High Dimensional Spatial Normalization of 11C PiB PET Images on a Population of Elderly, Mild Cognitive Impaired and Alzheimer Disease Patients (2008) (23)
Pupil response biomarkers for early detection and monitoring of Alzheimer's disease. (2013) (23)
Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort (2015) (23)
Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease using Cerebrospinal Fluid Biomarkers in the AIBL Study (2019) (23)
Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis (2016) (22)
Amyloid PET Ligands for Dementia. (2010) (22)
A&bgr;-related memory decline in APOE &egr;4 noncarriers: Implications for Alzheimer disease (2016) (22)
Relationship between amyloid and tau levels and its impact on tau spreading (2021) (22)
Localization of temporal lobe epileptic foci with iodine-123 iododexetimide cholinergic neuroreceptor single-photon emission computed tomography (1996) (22)
Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer (2005) (22)
Intracerebral haemorrhage: incidence and use of computed tomography. (1988) (22)
A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort (2017) (21)
The Women's Healthy Ageing Project: Fertile ground for investigation of healthy participants ‘at risk’ for dementia (2013) (21)
Klotho allele status is not associated with Aβ and APOE ε4–related cognitive decline in preclinical Alzheimer's disease (2019) (21)
Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition (2020) (21)
Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer’s disease (2018) (21)
A ‘Disease Severity Index’ to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia (2017) (21)
Convexity Subarachnoid Hemorrhage with PiB Positive Pet Scans: Clinical Features and Prognosis (2015) (21)
Cerebral Blood Flow and Aβ-Amyloid Estimates by WARM Analysis of [11C]PiB Uptake Distinguish among and between Neurodegenerative Disorders and Aging (2017) (21)
“Alzheimer's disease” is neither “Alzheimer's clinical syndrome” nor “dementia” (2019) (21)
18 F-florbetaben Ab imaging in mild cognitive impairment (2013) (20)
Research and standardization in Alzheimer's trials: Reaching international consensus (2013) (20)
Trajectories of depressive and anxiety symptoms in older adults: a 6‐year prospective cohort study (2018) (20)
Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. (2018) (19)
Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease. (2020) (19)
BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF (2017) (19)
High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer's Disease. (2016) (18)
Fluoro-2-deoxy-D-glucose (FDG)-PET in APOEepsilon4 carriers in the Australian population. (2008) (18)
β-Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men. (2016) (18)
Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease (2020) (18)
Positron Emission Tomographic Imaging in Stroke Cross-Sectional and Follow-Up Assessment of Amyloid in Ischemic Stroke (2015) (18)
POSTICTAL SPET IN EPILEPSY (1989) (17)
Management impact of FDG-PET in dementia: results from a tertiary center memory clinic. (2014) (17)
A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer’s Disease (2018) (17)
Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. (2018) (17)
Advances in Brain Amyloid Imaging. (2021) (17)
Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults. (2018) (16)
Computational analysis of PET by AIBL (CapAIBL): a cloud-based processing pipeline for the quantification of PET images (2015) (16)
Baseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years (2018) (16)
Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease. (2011) (16)
Severe Obstructive Sleep Apnea Is Associated with Higher Brain Amyloid Burden: A Preliminary PET Imaging Study. (2020) (16)
A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program and the Health Benefits for Older Adults at Risk of Alzheimer’s Disease: The AIBL Active-Study (2018) (16)
Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology (2020) (16)
2017 NIA-AA RESEARCH FRAMEWORK TO INVESTIGATE THE ALZHEIMER’S DISEASE CONTINUUM (2017) (15)
[Accepted Manuscript] Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial MRI study. (2017) (15)
11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case report. (2010) (15)
The Tau MeTeR composites for the generation of continuous and categorical measures of tau deposits in the brain (2017) (15)
In vivo microstructural heterogeneity of white matter lesions in healthy elderly and Alzheimer's disease participants using tissue compositional analysis of diffusion MRI data (2020) (15)
Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer’s Disease (2020) (15)
Reduced posterior cingulate binding of I-123 iodo-dexetimide to muscarinic receptors in mild Alzheimer’s disease (2005) (15)
Rates of age- and amyloid β-associated cortical atrophy in older adults with superior memory performance (2019) (15)
Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer's Disease. (2019) (15)
Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with 18F-AV133 and PET (2017) (15)
Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia (2016) (14)
OPTIMAL REFERENCE REGION TO MEASURE LONGITUDINAL AMYLOID-BETA CHANGE WITH 18F-FLORBETABEN PET (2016) (14)
Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults. (2019) (14)
Advances in molecular imaging for the diagnosis of dementia. (2009) (14)
Radiation Dosimetry of b-Amyloid Tracers 11 C-PiB and 18 F-BAY94-9172 (2009) (14)
Validation of a priori candidate Alzheimer’s disease SNPs with brain amyloid-beta deposition (2019) (14)
What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies (2020) (14)
Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. (2018) (13)
Case Report: 18F-MK6240 Tau Positron Emission Tomography Pattern Resembling Chronic Traumatic Encephalopathy in a Retired Australian Rules Football Player (2020) (13)
Effect of BDNF Val 66 Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer ’ s Disease : A Preliminary Study (2014) (13)
Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-β–negative cognitively normal individuals (2020) (13)
The preparation of 123/125I‐clioquinol for the study of Aβ protein in Alzheimer's disease (2005) (13)
Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral Aβ-Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study (2021) (13)
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. (2022) (12)
Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner. (2017) (12)
Longitudinal evaluation of the natural history of amyloid-β in plasma and brain (2020) (12)
La Lunga Attesa: Towards a Molecular Approach to Neuroimaging and Therapeutics in Alzheimer's Disease (2006) (12)
Relationship between Atrophy and Beta-Amyloid Deposition in Normal Elderly, Mild Cognitive Impairment and Alzheimer's Disease (2010) (12)
PIB-PET SEGMENTATION FOR AUTOMATIC SUVR NORMALISATION WITHOUT MR INFORMATION (2007) (12)
Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease (2018) (12)
Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study (2019) (12)
IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA. Authors' reply (2008) (11)
Aβ-related memory decline in APOE ε4 noncarriers (2016) (11)
Automatic detection of small spherical lesions using multiscale approach in 3D medical images (2013) (11)
Tractographic Threshold-Free Cluster Enhancement : Whole-Brain Statistical Analysis of Diffusion MRI Measures in the Presence of Crossing Fibres (2012) (11)
The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults (2018) (10)
Characteristics of subjective cognitive decline associated with amyloid positivity (2021) (10)
Early detection of amyloid load using 18F-florbetaben PET (2021) (10)
The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives (2021) (10)
Simultaneous emission transmission tomography using technetium-99m for both emission and transmission (1997) (10)
Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI (2021) (10)
Personal memory function in mild cognitive impairment and subjective memory complaints: results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing. (2014) (9)
Research and applications: MilxXplore: a web-based system to explore large imaging datasets (2013) (9)
Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer's Disease. (2017) (9)
Local intensity model: An outlier detection framework with applications to white matter hyperintensity segmentation (2011) (9)
Assessing Reactive Astrogliosis with 18F-SMBT-1 Across the Alzheimer Disease Spectrum (2022) (9)
Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients (2018) (9)
Tau imaging with PET: an overview of challenges, current progress, and future applications. (2017) (9)
First-in-Humans Evaluation of 18F-SMBT-1, a Novel 18F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis (2022) (9)
The Aβcentric Pathway of Alzheimer’s Disease (2007) (9)
Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease (2022) (9)
CapAIBL: Automated Reporting of Cortical PET Quantification Without Need of MRI on Brain Surface Using a Patch-Based Method (2016) (9)
A beta-amyloid and Tau Imaging in Dementia (2017) (9)
The Centiloid Scale: Standardization of amyloid imaging measures (2013) (9)
AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON THE BRAIN SURFACE (2019) (9)
Amyloid imaging in therapeutic trials: The quest for the optimal reference region (2015) (9)
Spline Based Inhomogeneity Correction for 11C-PIB PET Segmentation Using Expectation Maximization (2007) (9)
Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease (2021) (8)
APOEɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. (2017) (8)
In vivo tau imaging in Alzheimer's disease and other dementias (2012) (8)
Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults (2014) (8)
CONVERSION OF AMYLOID QUANTITATION WITH FLORBETAPIR SUVR TO THE CENTILOID SCALE (2016) (7)
II.P13 Amyloid load in Parkinson's Disease Dementia (PDD) and Lewy Body Dementia (LBD) measured with 11C-PIB PET (2006) (7)
Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies (2020) (7)
EVALUATION OF [F-18]-PI-2620, A SECOND-GENERATION SELECTIVE TAU TRACER, FOR THE ASSESSMENT OF ALZHEIMER’S AND NON-ALZHEIMER’S TAUOPATHIES (2018) (7)
Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum (2022) (7)
PREDICTING ALZHEIMER'S DISEASE FROM A BLOOD-BASED BIOMARKER PROFILE: RESULTS FROM AIPL AT 54 MONTHS (2014) (7)
Author Correction: Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions (2018) (7)
Imago Mundi, Imago AD, Imago ADNI (2014) (7)
In vivo microstructural heterogeneity of white matter lesions in Alzheimer’s disease using tissue compositional analysis of diffusion MRI data (2019) (7)
Framework : Toward a Biological Definition of Alzheimer ' s Disease (2018) (7)
Assessment of Aβ Deposition in Mild Cognitive Impairment with 18F-Florbetaben (2010) (7)
Safety of Disclosing Amyloid Imaging Results to MCI and AD Patients (2017) (7)
Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism (2020) (7)
Baseline White Matter Is Associated With Physical Fitness Change in Preclinical Alzheimer’s Disease (2020) (7)
Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: Predictive value of Aβ imaging with 18F-Florbetaben (2011) (6)
Advances in structural and molecular neuroimaging in Alzheimer's disease (2011) (6)
Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer’s Disease Patients and Correlates with Cognitive Performance (2020) (6)
Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume (2022) (6)
Age dependent prevalence of beta-amyloid positive 11C-PiB PET in healthy elderly subjects parallels neuropathology findings (2008) (6)
Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume (2022) (6)
APOE ε2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies (2022) (6)
Alterations in dorsal and ventral posterior cingulate connectivity in APOE ε4 carriers at risk of Alzheimer's disease (2015) (6)
Toward a Universal Readout for 18F-Labeled Amyloid Tracers: The CAPTAINs Study (2021) (6)
Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk. (2015) (6)
Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort (2022) (6)
18F-Florbetaben (FBB) PET SUVR quantification: Which reference region? (2015) (6)
A head-to-head comparison of cerebral blood flow SPECT and 18 F-FDG PET in the diagnosis of Alzheimer's Disease. (2020) (5)
Aβ amyloid, cognition and APOE genotype in the preclinical stages of Alzheimer's disease (2012) (5)
Synthetic microbleeds generation for classifier training without ground truth (2021) (5)
First results from human studies of a novel F-18 PET ligand for brain {beta}-amyloid imaging (2007) (5)
PET Imaging of brain muscarinic receptors with 18F-Fluorobenzyl-Dexetimide: A first in human study (2021) (5)
Amyloid-β, Tau, and 18F-Fluorodeoxyglucose Positron Emission Tomography in Posttraumatic Stress Disorder. (2019) (5)
Can I Smell Gas (or Is It Lilac)? Olfactory Semantic Deficits in Mild Cognitive Impairment and Alzheimer’s Disease (2010) (5)
Head-to-head comparison of 11C-PiB and 18F-AZD4694 for beta-amyloid imaging in aging and dementia (2012) (5)
AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON BRAIN SURFACE (2019) (5)
11C-PIB PET imaging in the differential diagnosis of dementia (2006) (5)
COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults (2019) (5)
COMPARISON OF THREE NORMATIVE DATA CORRECTION APPROACHES: A CROSS-SECTIONAL EVALUATION IN THE AIBL STUDY (2014) (5)
Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer’s disease (2020) (5)
IN VIVO IMAGING OF BRAIN MUSCARINIC RECEPTORS WITH 18F-FLUROBENZYL DEXETIMIDE: FIRST IN HUMAN STUDIES (2019) (5)
Comparative analysis of the Cancer Council of Victoria and the online Commonwealth Scientific and Industrial Research Organisation FFQ. (2015) (5)
Visual and QuantitativeAnalysis of Interictal SPECTwith Technetium-99m-HMPAOin Temporal Lobe Epilepsy (1991) (5)
Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study (2020) (5)
Self-reported confusion is related to global and regional β-amyloid: data from the Women’s healthy ageing project (2018) (5)
PET-only 18F-AV1451 tau quantification (2017) (5)
Risk of Dementia in Posttraumatic Stress Disorder (2020) (4)
A normalisation framework for quantitative brain imaging; application to quantitative susceptibility mapping (2017) (4)
Aβ Imaging in Aging, Alzheimer’s Disease and Other Neurodegenerative Conditions (2014) (4)
Australian prospective multi-centre PET data collection project -- Impact of FDG PET in oncology, epilepsy and cardiac patients (2007) (4)
Avoiding methodological bias in studies of amyloid imaging results disclosure (2019) (4)
Microbleeds and clinical trajectories: Results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging (2013) (4)
Manifold drived MR-less PiB SUVR normalisation (2012) (4)
Trajectories of Irregular Word Reading Ability as a Proxy for Premorbid Intelligence in Alzheimer’s Disease, Mild Cognitive Impairment, and Healthy Aging: A Longitudinal Study (2018) (4)
A web‐based normative data tool for assessing cognitive performance in healthy older Australians (2011) (4)
Rare genetically defined causes of dementia (2005) (4)
Deferiprone to delay dementia (the 3D trial) (2020) (4)
Mesial temporal tau in amyloid-β-negative cognitively normal older persons (2022) (4)
Untangling tau imaging (2016) (4)
Generating continuous and categorical measures from tau imaging studies with 18F-AV1451 and 18F-THK5351: The Tau MeTeR scale (2016) (4)
The natural history of the dynamics of beta-amyloid deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease (2013) (4)
Alzheimer's disease is associated with lower hemoglobin levels and anemia: The Australian Imaging Biomarker Lifestyle (AIBL) study of aging (2010) (4)
Generative atlases and atlas selection for C11-PIB PET-PET registration of elderly, mild cognitive impaired and Alzheimer disease patients (2008) (4)
MR-Less Surface-Based Amyloid Estimation by Subject-Specific Atlas Selection and Bayesian Fusion (2012) (4)
Quantitative approaches to amyloid imaging. (2011) (4)
Amyloid-beta: The seeds of darkness (2011) (4)
Investigating the synergistic relationship between sleep quality, physical activity, and levels of brain beta-amyloid (2015) (4)
Comorbidity of Cerebrovascular and Alzheimer's Disease in Aging. (2020) (3)
Neuroimaging within the Dominantly Inherited Alzheimer’s Network (DIAN): PET and MRI (2022) (3)
Larger temporal volume in asymptomatic elderly with high versus low beta-amyloid deposition (2010) (3)
Evaluation of GammaH2AX in Buccal Cells as a Molecular Biomarker of DNA Damage in Alzheimer’s Disease in the AIBL Study of Ageing (2020) (3)
β-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3 (2022) (3)
In vivo pattern of tau and beta-amyloid deposition in the brain might distinguish healthy individuals from those with preclinical Alzheimer's disease (2013) (3)
Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease? (2018) (3)
The heritability of amyloid burden in older adults: the Older Australian Twins Study (2021) (3)
Head‐to‐head comparison of cerebral blood flow single‐photon emission computed tomography and 18F‐fluoro‐2‐deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease (2021) (3)
THE TAU METER SCALE FOR THE GENERATION OF CONTINUOUS AND CATEGORICAL MEASURES OF TAU DEPOSITS IN THE BRAIN: RESULTS FROM 18F-AV1451 AND 18F-THK5351 TAU IMAGING STUDIES (2016) (3)
THE AUSTRALIAN DEMENTIA NETWORK (ADNET) CLINICAL QUALITY REGISTRY (2019) (3)
Web-based automated PET and MR quantification (2015) (3)
Predictors of cognitive decline at 18 month follow up among 1112 participants in the Australian imaging, biomarkers and lifestyle flagship study of ageing (AIBL) (2011) (3)
TAU PET IN A4: PRELIMINARY REPORT (2018) (3)
The Interaction Between Vascular Risk Factors, Cerebral Small Vessel Disease, and Amyloid Burden in Older Adults. (2022) (3)
F-florbetaben A β imaging in mild cognitive impairment (2013) (3)
Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimer’s Disease Dementia: A Measure of Objective Memory Impairment in Amnestic Mild Cognitive Impairment (2020) (3)
18F-Florbetaben-pet imaging in the differential diagnosis of dementia (2010) (3)
Divergent Network Patterns of Amyloid-β Deposition in Logopenic and Amnestic Alzheimer's Disease Presentations. (2016) (3)
Decrease in p3-Alcβ37 and p3-Alcβ40, products of Alcadein β generated by γ-secretase cleavages, in aged monkeys and patients with Alzheimer's disease (2019) (3)
Neutrophil-lymphocyte ratio in Alzheimer's disease: Data from the Australian Imaging Biomarker and Lifestyle study of ageing (2013) (3)
Voxel-based analysis of Alzheimer's Disease using apparent fibre density (2012) (3)
Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort (2015) (3)
CORRELATION OF AMYLOID PET EXPRESSED IN CENTILOID UNITS WITH NEUROPATHOLOGICAL FINDINGS IN ALZHEIMER’S DISEASE (2018) (3)
Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer’s Disease (2022) (3)
Aβ accumulation in non-demented individuals: A longitudinal F-18-flutemetamol study (2015) (3)
A NEGATIVE FLORBETABEN PET SCAN RELIABLY EXCLUDES AMYLOID PATHOLOGY AS CONFIRMED BY HISTOPATHOLOGY (2014) (3)
In vivo tau imaging in Alzheimer's disease and other dementias (2012) (3)
Human biodistribution and internal dosimetry of 4-[ 18F]fluorobenzyl-dexetimide: a PET radiopharmaceutical for imaging muscarinic acetylcholine receptors in the brain and heart (2020) (3)
Cognitive and affective predictors of subjective memory complaints in the Australian Imaging Biomarkers and Lifestyle (AIBL) study of aging: A cross-sectional analysis (2011) (2)
Monitored physical activity is associated with better cognitive performance in the elderly: A study from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (2010) (2)
Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases (2022) (2)
Amyloid imaging in Alzheimer's disease: Relationships to memory deficits, brain atrophy, and hypometabolism (2012) (2)
Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: Predictive value of Aβ imaging with 18F-Florbetaben (2011) (2)
IN VIVO TAU IMAGING WITH 18F-THK5105 AND 18F-THK5117 (2014) (2)
Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer’s Disease (2022) (2)
Cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma undergoing standard chemotherapy: a longitudinal feasibility study (2022) (2)
O1-04-03 Amyloid burden in ageing subjects with and without cognitive decline (2007) (2)
Cognitive consequences of high beta-amyloid levels in people with mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's disease (2013) (2)
Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition (2021) (2)
Biomarker-based prediction of cognitive decline in 270 nondemented older individuals: Three-year follow-up results from the Australian Imaging Biomarkers and Lifestyle study of Aging (AIBL) (2013) (2)
OPL204 Amyloid imaging in Lewy Body Dementia with 11C-PIB-PET (2005) (2)
Baseline data from the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing (2009) (2)
Beta-amyloid imaging and memory in a large cohort of elderly individuals (2008) (2)
Supervised method to build an atlas database for multi-atlas segmentation-propagation (2010) (2)
Genetic algorithm with logistic regression for Alzheimer's disease diagnosis and prognosis (2013) (2)
Combining PIB and FDG PET data to distinguish AD patients from normal controls: A multi-modal partial least square approach (2008) (2)
A surface based approach for cortical thickness comparison between PiB+ and PiB- healthy control subjects (2012) (2)
The interaction between physical activity and sleep on cognitive function and brain beta-amyloid in older adults (2022) (2)
Proceedings of the International Society for Magnetic Resonance in Medicine. Salt Lake City, Utah, USA (2013) (2)
Diet, neuroimaging biomarkers and Alzheimer's disease: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (2012) (2)
THE ASSOCIATION BETWEEN AMYLOID BURDEN AND SUB-CLINICAL DEPRESSION IN HEALTHY OLDER ADULTS (2014) (2)
Cognition, hippocampal volume and fibrillar Aβ burden as predictors of cognitive decline: Three-year follow-up results from AIBL (2012) (2)
Alzheimer's disease detection using 11C-PiB with improved partial volume effect correction (2009) (2)
Amyloid-β (Aβ)-Related Cerebral Amyloid Angiopathy Causing Lobar Hemorrhage Decades After Childhood Neurosurgery (2022) (2)
MESIAL TEMPORAL TAU BURDEN IN OLDER ADULTS WITH SUBJECTIVE MEMORY COMPLAINTS RELATES TO POORER MEMORY FUNCTION (2016) (2)
CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS (2014) (2)
EDUCATION AND PHYSICAL ACTIVITY IN RELATION TO FRAILTY AND WHOLE-BRAIN STRUCTURAL HEALTH IN ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND NORMAL AGING: RESULTS FROM THE AUSTRALIAN IMAGING, BIOMARKERS AND LIFESTYLE FLAGSHIP STUDY OF AGEING (AIBL) (2017) (2)
Cross-sectional and Longitudinal Analysis of the Relationship Between A β Deposition , Cortical Thickness , andMemory in Cognitively Unimpaired Individuals and in Alzheimer Disease (2013) (2)
Apparent fibre density: A novel MRI approach that identifies specific white matter tracts affected in Alzheimer's disease and MCI (2012) (2)
Rates of regional tau accumulation in ageing and across the Alzheimer's disease continuum: an AIBL 18F-MK6240 PET study (2022) (2)
Atrophy , hypometabolism and clinical trajectories in amyloid negative probable AD patients (2018) (2)
The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults (2022) (2)
Rates of conversion to MCI and Alzheimer's in the Australian Imaging, Biomarkers and Lifestyle (AIBL) cohort over 36 months (2012) (2)
Amyloid imaging (2011) (2)
Standardization of amyloid imaging (2010) (2)
DETECTION OF PRODROMAL ALZHEIMER'S DISEASE WITH 18F-FLORBETABEN Aβ IMAGING: A PROSPECTIVE OUTCOME STUDY (2014) (2)
Alzheimer’s disease research progress in Australia: The Alzheimer’s Association International Conference Satellite Symposium in Sydney (2021) (2)
AMYLOID β-RELATED COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE IS MODERATED BY APOE AND BDNF POLYMORPHISMS (2014) (2)
Automatic Detection of Cerebral Microbleed in SWI Using Radon Transform (2013) (2)
TO TAU OR TO MAO-B? MOST OF THE [F-18]-THK5351 SIGNAL IS BLOCKED BY SELEGILINE (2018) (2)
Differential Effects of APOE and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in Aβ− and Aβ+ Older Adults (2022) (2)
CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS (2014) (2)
Elevated PiB precedes dementia in autosomal dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (2)
18F‐MK6240 longitudinal tau PET in ageing and Alzheimer’s disease (2021) (2)
Nicotinic receptor imaging with 2-[18F]F-A-85380 PET does not differentiate early Alzheimer's disease patients from healthy controls (2007) (2)
O3-06-07 C-11 PIB PET amyloid imaging in aging and dementia (2006) (2)
Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions (2020) (1)
Progressive white matter abnormalities in autosomal dominant Alzheimer's disease: Results of the DIAN study (2012) (1)
Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease (2020) (1)
Aβ accumulation correlates with cognitive decline: results from the longitudinal AIBL study (2011) (1)
PTSD AND RISK OF ALZHEIMER’S DISEASE IN AUSTRALIAN VIETNAM VETERANS: AMYLOID AND TAU PET FINDINGS FROM AIBL-VETS (2017) (1)
GENETIC ANALYSIS OF THE STEROIDOGENESIS PATHWAY: ASSOCIATIONS WITH ALZHEIMER'S DISEASE RISK AND RELATED PHENOTYPES (2014) (1)
Early detection of amyloid load using 18F-florbetaben PET (2021) (1)
Longitudinal analysis of cortical thickness in PiB+ and PiB- healthy elderly controls (2012) (1)
From the CSIRO Preventative Health National Research Flagship (2012) (1)
Brain Imaging in Epilepsy : A Meta-Analysis (2006) (1)
FDG-PET improves diagnosis in patients presenting with focal onset variants of Alzheimer's disease (2014) (1)
COMPARISON OF 18F-FLORBETABEN QUANTIFICATION RESULTS USING MR-BASED AND MR-LESS CAPAIBL: VALIDATION AGAINST HISTOPATHOLOGY (2017) (1)
Determining rate of decline in pre-AD and AD AIBL participants using a brief computerized battery (2010) (1)
IMPLEMENTING THE CENTILOID TRANSFORMATION FOR 18F-FLORBETABEN AND 18F-NAV4694 USING CAPAIBL (2017) (1)
Biomarker-based prediction of cognitive decline in 270 nondemented older individuals: Three-year follow-up results from the Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL) (2013) (1)
IC-P3-226: Prevalence of Aβ positive 11C-PiB PET studies in healthy elderly subjects parallels neuropathology findings (2008) (1)
Drisapersen treatment for Duchenne muscular dystrophy: results of a 96-week follow-up of an open-label extension study following two placebo-controlled trials (2014) (1)
Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology (2020) (1)
Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults (2017) (1)
A longitudinal study of {beta}-amyloid deposition with 11C-PiB-PET (2008) (1)
Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study (2022) (1)
O1-04-06 Correlation of memory dysfunction and amyloid burden in mild cognitive impairment (2007) (1)
AN EXPLORATORY MOLECULAR IMAGING STUDY TARGETING Aβ WITH A NOVEL 8-OH QUINOLINE IN ALZHEIMER’S DISEASE (THE PBT2-204 IMAGINE STUDY) (2016) (1)
COMPARISON OF 18F-FLORBETABEN QUANTIFICATION RESULTS USING MR-BASED AND MR-LESS CAPAIBL: VALIDATION AGAINST HISTOPATHOLOGY (2017) (1)
IMPLEMENTING THE CENTILOID TRANSFORMATION FOR 18F-FLORBETABEN AND 18F-NAV4694 USING CAPAIBL (2017) (1)
Comparing Amyloid PET Tracers and Interpretation Strategies: First Results from the CAPTAINs Study (2018) (1)
Positron emission tomography in neuroscience (2005) (1)
CenTauRz: A standardized quantification of tau PET scans (2022) (1)
Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease (2022) (1)
The bimodality of healthy ageing: How do the differing profiles of healthy controls compare to patients with mild cognitive impairment? (2009) (1)
Using the Artificial Neural Network to discriminate between normal controls with different APOE e4 genotypes and probable AD cases in PIB-PET studies (2009) (1)
Aβ accumulation correlates with cognitive decline: results from the longitudinal AIBL study (2011) (1)
A Framework to Objectively Identify Reference Regions for Normalizing Quantitative Imaging (2018) (1)
The effects of APOE4 on the rate of atrophy and Aβ deposition in asymptomatic elderly (2011) (1)
Longitudinal assessment of A beta accumulation in non-demented individuals: A F-18-flutemetamol study (2015) (1)
Dynamic of Beta-amyloid deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a PiB-PET longitudinal study (2011) (1)
Genome‐wide study of the human lipidome and links to Alzheimer’s disease risk (2020) (1)
A data-derived Aβ biomarker model computed using longitudinal PIB data from AIBL (2012) (1)
Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease (2014) (1)
DOES ENHANCED RECONSTRUCTION METHODOLOGY CHANGE THE QUANTIFICATION OF AMYLOID PET WITH FLUMETAMOL? (2014) (1)
Test-retest variability of [18F]BAY 94-9172 studies in Alzheimer's disease and normal ageing (2009) (1)
Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF Aβ42 moderates the association between insulin resistance and increased CSF tau levels (2022) (1)
Dependence and resource utilization in MCI and Alzheimer’s patients participating in the AIBL study (2011) (1)
Focal Ab-amyloid deposition precedes cerebral microbleeds and Superficial siderosis: a case report (2017) (1)
11C-PiB-postmortem Aβ plaque load correlation (2010) (1)
Cognitive deficits four decades after traumatic brain injury in Australian Vietnam war veterans (2021) (1)
A snapshot of brain and cognition in healthy mid-life and older adults (2022) (1)
FIXEL-BASED ANALYSIS OF FIBRE TRACT DEGENERATION IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE (2017) (1)
P1-153: The relationship between olfactory identification and memory and Abeta burden in Alzheimer's disease, mild cognitive impairment and healthy aging: A PIB-PET study (2008) (1)
FDG-PET improves diagnosis in patients presenting with focal onset dementias � (2015) (1)
CONSIDERATION OF PRECLINICAL AD FROM THE PERSPECTIVE OF NORMAL AGING: AMYLOID-β RELATED CHANGES IN FLUID AND CRYSTALLIZED INTELLIGENCE IN A ROBUST SAMPLE OF HEALTHY OLDER ADULTS (2017) (1)
Neuropsychological predictors of autobiographical memory impairment in mild cognitive impairment (MCI) (2013) (1)
Evaluation of the novel 18F‐labeled PET tracer SMBT‐1 for imaging astrogliosis in healthy elderly controls and A+/T+/(N+) Alzheimer's disease patients (2020) (1)
Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study (2012) (1)
Assessing Aβ & tau pathology in Vietnam war veterans with chronic Post-Traumatic Stress Disorder (2016) (1)
Cognitive change and Aβ deposition in MCI subjects studied with serial 18F-florbetaben PET over 2 years (2012) (1)
Pattern of A{beta} deposition in familial Alzheimer's disease is irrespective of mutation type or cognitive status (2008) (1)
Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer’s Disease (2023) (1)
Diminished white matter integrity four decades after traumatic brain injury in Vietnam War veterans (2021) (1)
Interaction between 18F-THK5317, 18F-flutemetamol SUVR, and cortical thickness (2015) (1)
COGNITIVE SUPER-AGING VERSUS TYPICAL AGING IN COMMUNITY-DWELLING OLDER ADULTS: LONGITUDINAL TRAJECTORIES IN GLOBAL CORTICAL THICKNESS OVER SIX YEARS (2017) (1)
PET image harmonization using smoothing-CycleGAN (2022) (1)
Dynamic of beta-amyloid deposition in healthy elderly, mild cognitive impairment and alzheimer's disease: a PiB-PET longitudinal study (2011) (1)
Investigating cardiovascular risk factors on cognition: A two-cohort study (2012) (1)
HIGHER AB BURDEN IN HEALTHY APOE-E4 CARRIERS IS ASSOCIATED WITH SUBJECTIVE MEMORY COMPLAINTS: RESULTS FROM THE FLUTEMETAMOL AND PIB AIPL COHORTS (2014) (1)
Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β (2022) (1)
ADVANCED DIFFUSION MRI ENABLES IN VIVO INVESTIGATION OF MICROSTRUCTURAL HETEROGENEITY OF WHITE MATTER HYPERINTENSITIES IN ALZHEIMER’S DISEASE (2018) (1)
Plasma p217+tau vs NAV4694 amyloid and MK6240 tau PET across the Alzheimer continuum. (2022) (1)
The cognitive and brain volumetric trajectories of healthy elderly controls with either Alzheimer’s pathology, neurodegeneration (SNAP), or both (2015) (1)
DETECTION OF PRODROMAL ALZHEIMER'S DISEASE WITH 18F-FLORBETABEN AB IMAGING: A PROSPECTIVE OUTCOME STUDY (2014) (1)
The effect of vascular risk factors on cognition in older adults: Data from the AIBL study (2012) (1)
Correlation between white matter hyperintensities in MRI-FLAIR and 11C-PiB PET retention. A new potential for early identification of disease (2009) (1)
A{beta} burden correlates with memory impairment in non-demented subjects but plateaus in established Alzheimer's disease: A PIB-PET cross sectional study (2007) (1)
In vivo quantification of striatal VMAT2 with [F-18] AV133 (2009) (1)
Plasma high‐density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume (2022) (1)
Comprehensive genetic analysis of the human lipidome identifies novel loci controlling lipid homeostasis with links to coronary artery disease (2021) (1)
Phantom measurement predicts the impact of image reconstruction on Florbetapir SUVR quantification (2019) (1)
Comparison of 11C-PiB and 18F-AZD4694 for A{beta} imaging in ageing and dementia (2012) (1)
β-Amyloid and Tau Imaging in Chronic Traumatic Brain Injury: A Cross-sectional Study. (2022) (1)
P2-006: Baseline data from a multi-centre, prospective longitudinal study of ageing in 1000 volunteers (the AIBL study) (2008) (1)
Worster-Drought Syndrome (Familial British Dementia): A Case Report (2010) (1)
Novel CYP1B1-RMDN2 Alzheimers disease locus identified by genome-wide association analysis of cerebral tau deposition on PET (2023) (1)
Imago Mundi, Imago AD, Imago ADNI (2014) (1)
Association between amyloid-beta deposition and cortical thickness in dementia with Lewy bodies (2022) (1)
REVISITING, REVISING AND REFINING THE NATURAL HISTORY OF AB DEPOSITION AND ITS EFFECTS ON NEURODEGENERATION AND COGNITIVE DECLINE IN SPORADIC ALZHEIMER’S DISEASE (2016) (1)
Elevated levels of synaptic protein GAP‐43 associate with brain tauopathy, atrophy and cognition in Alzheimer’s disease (2020) (1)
ADVANCED DIFFUSION MRI ENABLES IN VIVO INVESTIGATION OF MICROSTRUCTURAL HETEROGENEITY OF WHITE MATTER HYPERINTENSITIES IN ALZHEIMER’S DISEASE (2018) (1)
Plasma beta-amyloid levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden (2013) (1)
In vivo pattern of tau and beta-amyloid deposition in the brain might distinguish healthy controls from preclinical Alzheimer's disease (2013) (1)
Does cognitive decline occur decades after moderate to severe traumatic brain injury? A prospective controlled study (2021) (1)
Corrigendum: Corrigendum to 'Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment'. (2016) (1)
Mediterranean diet adherence is associated with less cerebral amyloid accumulation over time: Data from the australian imaging, biomarkers, and lifestyle study of ageing (2015) (1)
IMPLEMENTING THE ATN CLASSIFICATION IN AIBL (2017) (1)
Comparison of biomarkers for the prediction of cognitive decline (2010) (1)
CORRECTING FOR PET SCANNER CHANGES IN LONGITUDINAL STUDIES (2019) (1)
EFFECTS OF MAPT OVER BRAIN GREY MATTER ATROPHY IN THE AIBL COHORT (2016) (1)
P2-317 In vitro characterization of PIB binding to α-synuclein (2006) (1)
THE INFLUENCE OF LOW-DENSITY LIPOPROTEINS ON NEOCORTICAL AMYLOID LOAD IN THE AUSTRALIAN IMAGING BIOMARKER AND LIFESTYLE STUDY (2017) (1)
Magnetic resonance imaging subtypes in subjective cognitive decline (2020) (1)
Correlating the frontal presentation of Alzheimer's disease with frontal metabolism as measured by FDG-PET (2012) (1)
81 In vivo tau imaging with PET (2012) (1)
Ten-year MRI changes and FBB-PET: Results from the Women's Healthy Aging Project (WHAP) (2013) (1)
Normative neuropsychology datasets free from prodromal Alzheimer's disease (AD) cases may improve sensitivity for detecting early cognitive decline: Data from the AIBL study (2011) (1)
Galantamine improves cognitive performance without effecting nicotinic receptors in early Alzheimer's disease as measured by 2[18F]F-A-85380 PET (2007) (1)
CORTICAL CEREBRAL MICROINFARCTS ON 3T MRI IN ALZHEIMER’S DISEASE AND MILD COGNITIVE IMPAIRMENT (2017) (1)
Longitudinal analysis of cortical thickness in PiB+ and PiB- healthy elderly controls (2012) (1)
VISUAL ASSESSMENT OF β-AMYLOID PET SCAN IS IMPROVED BY CAPAIBL (2018) (1)
Prevalence and growth of cerebral microhemorrhages in autosomal dominant Alzheimer's disease (2013) (1)
The AIBL study: Baseline data from a multicenter, prospective longitudinal study of ageing in 1,100 volunteers (2009) (1)
Prevalence and growth of cerebral microhemorrhages in autosomal dominant Alzheimer's disease (2013) (1)
Longitudinal Trajectories in Cortical Thickness and Volume Atrophy: Superior Cognitive Performance Does Not Protect Against Brain Atrophy in Older Adults. (2021) (0)
MEDITERRANEAN DIET ADHERENCE IS ASSOCIATED WITH ATTENUATED CORTICAL THINNING IN AN AUSTRALIAN STUDY OF AGEING (2017) (0)
The Australian Biomarker, Imaging and Lifestyle Study: Phase I amyloid imaging results (2009) (0)
P3-084: Cerebrospinal fluid Tau and Aβ measurement and amyloid PET imaging in neurodegenerative diseases (2008) (0)
A voxel-based morphometry study of volumetric MRI in familial Alzheimer's disease (2012) (0)
Towards a universal cortical tau sampling mask (2020) (0)
Beta-amyloid and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease (2013) (0)
Longitudinal evaluation of basal forebrain atrophy and its association with beta-amyloid burden and hippocampal volume in Alzheimer's disease (2013) (0)
A Machine Learning Approach for Computer-Aided Detection of Cerebral Microbleed Using High-order Shape Features (2014) (0)
Progress of the australian imaging, biomarkers, and lifestyle (AIBL) cohort with 72 months of assessment: Attrition, disease progression, and mortality (2015) (0)
A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort (2017) (0)
Centiloid harmonisation across PET cameras without using paired scan (2022) (0)
FDG-PET and dopamine and serotonin transporter SPECT to distinguish dementia with Lewy bodies from Alzheimer's disease (2004) (0)
Towards a universal cortical tau sampling mask (2021) (0)
Using ApoE ε4 carriage as a benchmark for modelling clinically meaningful treatment effects in clinical trials of preclinical Alzheimer’s disease (2015) (0)
O2-13-04 WHITE MATTER HYPERINTENSITIES AND CSF BIOMARKERS IN RELATION TO CLINICAL SYMPTOM ONSET IN PRECLINICAL ALZHEIMER’S DISEASE (2018) (0)
Head‐to‐Head comparison between Philips Gemini TF64 and Siemens Biograph Vision 600 for brain amyloid Centiloid quantitation (2022) (0)
TAU, Aβ-AMYLOID, BRAIN STRUCTURE AND COGNITIVE FUNCTION FOLLOWING SERVICE-RELATED TRAUMATIC BRAIN INJURY IN AUSTRALIAN VIETNAM WAR VETERANS (2018) (0)
WHITE MATTER HYPERINTENSITIES, AMYLOID-β, AND RISK OF COGNITIVE DECLINE IN HEALTHY OLDER PEOPLE (2019) (0)
Self-reported confusion is related to global and regional β-amyloid: data from the Women’s healthy ageing project (2017) (0)
Tau and Beta-Amyloid Deposition, Micro Hemorrhage and Brain Function after Traumatic Brain Injury in War Veterans (2016) (0)
Identifying protein biomarkers for early diagnosis of Alzheimer's disease (2010) (0)
Evaluation of the novel F-18-labeled PET tracer SMBT-1 for imaging astrogliosis in Alzheimer's disease (2020) (0)
INCREASED PROTEIN AND FIBRE INTAKE IS ASSOCIATED WITH HIGHER PERFORMANCE IN THE AIBL PACC SCORE IN COGNITIVELY NORMAL ADULTS: AUSTRALIAN IMAGING, BIOMARKERS AND LIFESTYLE (AIBL) STUDY (2018) (0)
IC-P2-149: In vivo assessment of β-amyloid deposition: A longitudinal study (2008) (0)
A beta ACCUMULATION CORRELATES WITH COGNITIVE DECLINE: RESULTS FROM THE AIBL LONGITUDINAL STUDY (2011) (0)
FAILURE TO SHOW A PRACTICE EFFECT ON MEMORY TESTING IS A COGNITIVE MARKER OF MCI DUE TO ALZHEIMER'S DISEASE (2016) (0)
IC-P1-046: Examining the regional specificity between Aβ burden and cognition (2008) (0)
REFINING THE NATURAL HISTORY OF GLOBAL AND REGIONAL Aβ-AMYLOID DEPOSITION IN SPORADIC ALZHEIMER’S DISEASE (2017) (0)
GLOBAL TAU BURDEN CORRELATES WITH BASAL FOREBRAIN ATROPHY IN HEALTHY AGING SUBJECTS (2017) (0)
Higher coffee consumption is associated with slower cognitive decline and Aβ‐amyloid accumulation over 126 months: Data from the AIBL study (2021) (0)
O1-04-02 Initial results from human studies of a novel F-18 PET ligand for brain beta-amyloid imaging (2007) (0)
Validation of SPET-to-MRI co-registration in the brain (1999) (0)
Radiation dosimetry of the amyloid imaging agent 18F-BAY94-9172 in humans (2008) (0)
AiblWHAP: Methodology and baseline characteristics of a population-based sample recruited for a longitudinal study of risk factors and later-life cognitive decline (2012) (0)
Clinical utility of the cogstate brief battery in Alzheimer's disease–related memory impairment (2013) (0)
CSF P-TAU IS CORRELATED WITH TAU PET, WHILE Aβ PET CORRELATES WITH Aβ1-42 AND THE T-TAU/Aβ1-42 RATIO (2017) (0)
Cross-sectional cerebral volumetric differences and associations with estimated time to age-at-onset in familial Alzheimer's disease: Findings from the DIAN study (2012) (0)
Stabilised vs standard 99mTc HMPAO for the localisation of epileptic foci using ictal injection - a comparison (2000) (0)
PLASMA BIOMARKERS OF NEOCORTICAL AMYLOID BURDEN: AN IN-DEPTH PLASMA PROFILE USING LC-MS (2016) (0)
Prediction of Aß and clinical outcome in patients with MCI with neuropsychological tests (2012) (0)
IC-P-022 C-11 PIB PET amyloid imaging in ageing and dementia (2006) (0)
BRAIN BETA-AMYLOID, VASCULAR FACTORS, AND COGNITION: 54-MONTH FOLLOWUP RESULTS FROM THE AIPL STUDY (2014) (0)
VISUAL ASSESSMENT OF β-AMYLOID PET SCAN IS IMPROVED BY CAPAIBL (2018) (0)
Brain age in chronic traumatic brain injury (2022) (0)
The anti‐amyloid treatment in asymptomatic Alzheimer’s disease (A4) study: Report of screening and recruitment characteristics of the Melbourne composite site (2020) (0)
Alzheimer's disease-related changes in plasma brain-derived neurotrophic factor levels: Data from the AIBL study (2012) (0)
Test-retest variability studies in Alzheimer's disease and normal ageing of the new amyloid imaging agent [18F]BAY 94-9172 (2009) (0)
Mapping the association between tau-PET and Aβ-amyloid-PET using deep learning (2022) (0)
TAU, Aß AND COGNITION IN HEALTHY ELDERLY: PRELIMINARY DATA FROM THE AIBL COHORT (2016) (0)
Cross‐sectional and longitudinal comparison of 18F‐MK6240 and 18F‐Flortaucipir in populations matched for centiloid, age and MMSE (2022) (0)
UTILITY OF THE COGNIGRAM BRIEF BATTERY IN ASSESSING COGNITIVE CHANGES ASSOCIATED WITH AB AND APOE GENOTYPE IN PRECLINICAL ALZHEIMER'S DISEASE (2014) (0)
Molecular imaging: Present and future prospects (2009) (0)
Subjective Memory Complaints and Cognitive Tests in the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) (2011) (0)
QUANTITATIVE SUSCEPTIBILITY MAPPING OF THE HIPPOCAMPUS PREDICTS HIPPOCAMPAL ATROPHY IN A b + ELDERLY CONTROLS AND ALZHEIMER’S DISEASE PATIENTS (2017) (0)
KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden (2018) (0)
Alzheimer's disease–related changes in plasma cortisol levels and gene involvement in the AIBL study (2012) (0)
Correlation between Amyloid Burden and Memory Impairment: A C-PIB PET Cross Sectional Study (2008) (0)
Detectable levels of white matter PHF-tau in Alzheimer's disease (2013) (0)
MR-less cortical surface-projection of PET images from 11C- and 18F-labeled radiotracers (2013) (0)
IC-P-012 C-11 PIB and F-18 FDG in the diagnosis of Alzheimer’s disease (2006) (0)
P-066 Characterization of PIB binding to white matter (2007) (0)
EXAMINING THE RESILIENCE OF SUPERAGERS: RISK OF CLINICAL PROGRESSION AND Aβ-ASSOCIATED MEMORY DECLINE OVER 8 YEARS (2018) (0)
PLASMA BIOMARKER WITH HIGH ACCURACY IN PREDICTING BRAIN AMYLOID-β BURDEN: INITIAL RESULTS ACROSS TWO INDEPENDENT LARGE COHORTS—NCGG (JAPAN) AND AIBL (AUSTRALIA) (2018) (0)
The effect of rapid cognitive decline in MCI and Alzheimer's disease on level of dependence, resource utilization, carer satisfaction, burden and attitudes to aging (2013) (0)
66 Brain imaging in early detection of Alzheimer's disease and other dementias (2012) (0)
Establishing apolipoprotein J as a potential candidate for Alzheimer's disease biomarker panel: Australian Imaging, Biomarker and Lifestyle (AIBL) flagship study of aging (2013) (0)
A retinal hyperspectral imaging biomarker for Alzheimer’s disease: Preliminary study of the influence of eye diseases on imaging scores (2020) (0)
AMYLOID BURDEN IS INDEPENDENT OF CEREBROVASCULAR BURDEN, BUT HYPERTENSION PROMOTES AMYLOID ACCUMULATION OVER TIME (2018) (0)
Combining white matter density and atrophy information to improve the characterization of axonal loss in Alzheimer's disease (2013) (0)
REGIONAL ASSOCIATION BETWEEN CORTICAL VOLUMES AND IMAGING TAU PATHOLOGY USING 18F-AV1451 AND 18F-THK5351 (2016) (0)
A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer’s Disease (2016) (0)
Correlation of PiB-PET to post-mortem A{beta} plaque load (2010) (0)
Investigation of fibre-specific white matter reductions in Alzheimer’s disease and mild cognitive impairment (2018) (0)
Establishing apolipoprotein E as a biomarker for Alzheimer's disease: Australian Imaging, Biomarker and Lifestyle (AIBL) Flagship Study of Ageing (2012) (0)
Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals (2022) (0)
Retinal vascular parameters as biomarkers for Alzheimer's disease (2011) (0)
Amyloid angiopathy may contribute to white‐matter hyperintensities in Alzheimer’s disease (2020) (0)
Examining the structural correlates of amyloid‐beta in people with DLB (2021) (0)
Implementation and Adoption of the Family Check-Up in a Pediatric Setting. (2015) (0)
PLASMA CORTISOL, AMYLOID-B, AND COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER’S DISEASE (2016) (0)
18F-AV-133 VMAT2 imaging in the differential diagnosis of dementia with Lewy Bodies from Alzheimer's disease (2010) (0)
VERBAL LEARNING AND BETA-AMYLOID: REPEATED ADMINISTRATION OF THE INTERNATIONAL SHOPPING LIST TEST (2018) (0)
NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN (2014) (0)
Normative data from the AIBL study: Language, visuoconstruction, and executive functioning in a large healthy elderly cohort (2010) (0)
BDNF, Aβ, and cortical atrophy in preclinical Alzheimer's disease (2015) (0)
Gene combination associations with Alzheimer's disease risk and quantitative traits in the AIBL study (2012) (0)
The Australian Imaging, Biomarkers and Lifestyle-Rate of Change sub-study (AIBL-ROCS): Rationale, design, acceptability and pilot data for the first three months of assessment (2012) (0)
Objectively measured physical activity and cognition in cognitively normal older adults: A longitudinal analysis of the Australian Imaging Biomarkers and Lifestyle (AIBL) study (2022) (0)
PET IMAGING OF BRAIN MUSCARINIC M1 RECEPTORS WITH F-18-FLUROBENZYL DEXETIMIDE: FIRST IN HUMAN STUDIES (2019) (0)
Aβ-related memory decline in preclinical Alzheimer's disease is delayed in ApoE-ɛ4 non-carriers (2015) (0)
Plasma copper and ceruloplasmin are not altered in Alzheimer's disease: Baseline data in the Australian Imaging Biomarker Lifestyle (AIBL) study of Ageing (2011) (0)
Cognitive & Behavioral Assessment Sensitivity of composite scores to amyloid burden in preclinical Alzheimer'sdisease:IntroducingtheZ-scoresofAttention,Verbalfluency, and Episodic memory for Nondemented older adults composite score (2016) (0)
Plasma glial fibrillary acidic protein is associated with reactive astrogliosis assessed via 18F‐SMBT‐1 PET (2022) (0)
Sigmoidal kinetics of BETA-AMYLOID deposition: Twenty-year interval between normality and fully developed Alzheimer's disease (2012) (0)
Achieving physical activity guideline recommendation in older adults at risk of cognitive deterioration (2016) (0)
A novel approach using 123I-iodophenyl pentadecanoic acid (IPPA) to investigate the effect of perhexiline on cardiac metabolism in sheep (1999) (0)
MIDLIFE VASCULAR RISK, APOLIPOPROTEIN E-E4, AND AMYLOID STATUS 20 YEARS LATER: RESULTS FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
GLOBAL TAU BURDEN CORRELATES WITH BASAL FOREBRAIN ATROPHY IN HEALTHY AGING SUBJECTS (2017) (0)
74. Analysis of brain SPET with the statistical parametric mapping package SPM99 (2000) (0)
IC-P-084 Nicotinic receptor upregulation and the cognitive effects of galantamine in Alzheimer’s disease: A human in vivo study using [18F]F-A-85380 PET (2006) (0)
Cerebral microbleeds in dementia with Lewy bodies. (2022) (0)
AGE INCREASES RATE OF AB- AND E4-RELATED MEMORY DECLINE IN PRECLINICAL ALZHEIMER’S DISEASE (2016) (0)
PiB as antecedent biomarker of Alzheimer's disease (2009) (0)
PRECLINICAL EFFECTS OF Aβ DEPOSITION ON EPISODIC MEMORY AND DISEASE PROGRESSION (2014) (0)
Suboptimal sleep efficiency and duration predicts rate of accumulation of Aβ‐ Amyloid in cognitively normal older adults (2022) (0)
Efficacy and reliability of the visual assessment of 18F-florbetaben PET scans in the detection of beta-amyloid neuritic plaques in the brain (2014) (0)
omers can disrupt normal neuronal homeostasis by triggering focal accumulation of axonal tau, loss of the polarized distribution of tau and dysregulation of fast axonal transport (2017) (0)
P1-071 INTENSITY OF DEMENTIATHROUGH LATENT VARIABLE MODELLING (I-DELV) IN THE AIBL COHORT (2019) (0)
P-092 Nicotinic receptors are not responsible for improved cognitive performance by galantamine in early Alzheimer’s disease: A 2-[18F]f-a-85380 PET study (2007) (0)
101. Brain Amyloid Imaging with 11C-PIB PET (2009) (0)
PARTIAL VOLUME CORRECTION USING EITHER PMOD ® OR CAPAIBL ® DOES LITTLE TO IMPROVE 18F-AV1451 PET QUANTIFICATION (2018) (0)
THK523 selectively binds to neurofibrillary tangles and neuropils in people with Alzheimer's disease (2013) (0)
HYPOMETABOLISM ASSOCIATEDWITH DEPRESSIVE SYMPTOMS IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE IMPAIRMENT (SCI) (2015) (0)
Effect of Aβ burden and apolipoprotein E-ε4 on cognitive decline at 18 months in healthy older adults (2012) (0)
Beta-amyloid imaging with 18F-BAY94-9172 (AV1/ZK) PET in the differential diagnosis of Alzheimer's disease from fronto-temporal lobar degeneration (2008) (0)
Review Inflammation following stroke (2006) (0)
Between SNAP and a hard Aβ rock: Characterizing the fate of preclinical Alzheimer's disease (2015) (0)
TAU IMAGING WITH 18F-MK6240 IN ALZHEIMER’S DISEASE AND OTHER DEMENTIAS (2019) (0)
O1-02-07: In vivo characterization of 18F-BAY94-9172: A novel β-amyloid PET ligand for the diagnosis of Alzheimer's disease (2008) (0)
AMYLOID PET IS MORE THAN JUST POSITIVE OR NEGATIVE: AMYLOID LEVEL IMPACTS RISK OF CLINICAL PROGRESSION IN NORMAL INDIVIDUALS (2019) (0)
ASSESSING THE ACCURACY OF A CT-BASED APPROACH TO THE PARTIAL VOLUME CORRECTION OF FLUTEMETAMOL-PET IMAGES (2014) (0)
How lifestyle shapes the brain: Associations between physical activity, sleep, beta‐amyloid and cognitive function in older adults (2021) (0)
Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia (2016) (0)
Differential diagnosis of dementia with Lewy bodies from Alzheimer's disease using [18F]-AV-133, a novel PET tracer for VMAT2 (2010) (0)
In an amnestic MCI population, those with high PIB binding perform more poorly on memory tests than those with low binding (2010) (0)
The consequences of Aβ deposition in aging and Alzheimer's disease: Results from 366 elderly subjects (2011) (0)
2018 NIA-AA Research Framework to Investigate the Alzheimer ’ s Disease Continuum 1 2 DRAFT 7-18-17 3 4 5 Clifford (2017) (0)
Longitudinal modeling of joint PIB/MRI changes in Alzheimer's disease (2012) (0)
One year tau progression measured with F‐18 MK6240 PET (2020) (0)
REGIONAL ASSOCIATION BETWEEN CORTICAL VOLUMES AND IMAGING TAU PATHOLOGY USING 18F-AV1451 AND 18F-THK5351 (2016) (0)
RECEIVER OPERATING CHARACTERISTICS (ROC) OF FLOW AND AMYLOID LOAD INDICES FROM BRAIN MAPS OF [11C]PIB RETENTION IN ALZHEIMER'S DISEASE (2014) (0)
Longitudinal evaluation of basal forebrain atrophy and its association to beta-amyloid burden and hippocampal volume in Alzheimer's disease (2013) (0)
Progressive white matter abnormalities in autosomal-dominant Alzheimer's disease: Results of the DIAN study (2012) (0)
Associatioin of Plasma Aβ Peptides with Blood Pressure in the Elderly (2020) (0)
Empirically derived composite cognitive test scores to predict preclinical and clinical stages of Alzheimer’s disease (2021) (0)
Healthy subjects with abnormal levels of amyloid‐B and tau have lower cortical volumes in the mesial temporal region (2020) (0)
Healthy older adults in the AIBL cohort at risk for cognitive decline (2011) (0)
BDNF, Aβ, and cortical atrophy in preclinical Alzheimer's disease (2015) (0)
DIFFERENTIAL RISK FACTORS FOR PROGRESSION TO MCI/DEMENTIA BY AMYLOID-BETA STATUS (2018) (0)
Cognitive change and beta-amyloid deposition in MCI subjects studied with serial 18F-Florbetaben PET over 2 years (2012) (0)
When is Progressive Aphasia Due to Alzheimer's Disease? A PIB-PET Study (2010) (0)
IN54-TH-01 Biomarkers for Alzheimer's disease from large cohort studies (2009) (0)
Cerebral microhaemorrhage and brain A{beta} in healthy ageing and Alzheimer's disease (2011) (0)
Association between cardiovascular risk and cognitive measures among older adults at risk of cognitive decline (2016) (0)
Amyloid imaging in differential diagnosis of Alzheimer's disease dementia (2012) (0)
C-11 PIB PET imaging in atypical presentation of Alzheimer's disease (2006) (0)
313: Imaging brain amyloid in ageing and dementia with C-11 PIB PET (2007) (0)
Risk factors for falls in preclinical and prodromal Alzheimer’s disease and dementia due to Alzheimer’s disease: Findings from the Australian Imaging, Biomarker and Lifestyle study of ageing (AIBL) (2020) (0)
THE LEWY STUDY: AN AUSTRALIAN LONGITUDINAL COHORT STUDY OF DEMENTIA WITH LEWY BODIES (2019) (0)
Combining two large clinical cohorts (AIBL and ADNI) to identify multiple lipid metabolic pathways in prevalent and incident Alzheimer's disease. (2020) (0)
Characteristics of the neighborhood built environment are associated with MRI brain volumetric and amyloid beta burden measures: Findings from the australian imaging, biomarkers, and lifestyle (AIBL) study (2015) (0)
The bimodality of healthy ageing: How do the differing profiles of healthy controls compare to patients with mild cognitive impairment? (2009) (0)
LONGITUDINAL ASSESSMENT OF Aβ ACCUMULATION WITH FLUTEMETAMOL (2017) (0)
P2-291 C-11 PIB and F-18 FDG in the diagnosis of Alzheimer’s disease (2006) (0)
DIFFERENCE IN THE RATE OF COGNITIVE CHANGE BETWEEN INDIVIDUALS WITH AND WITHOUT VASCULAR RISK FACTORS: A LONGITUDINAL STUDY (2016) (0)
Longitudinal modeling of joint PiB/MRI changes in Alzheimer's disease (2012) (0)
Modulation of beta-amyloid-related cognitive decline by brain-derived neurotrophic factor Val66Met polymorphism in preclinical Alzheimer's disease (2013) (0)
Apparent fibre density: A novel MRI approach that identifies specific white matter tracts affected in Alzheimer's disease and MCI (2012) (0)
P1-238: The Australian biomarker, imaging and lifestyle study: Preliminary PiB results (2008) (0)
Characterizing patterns of atrophy between cognitively unimpaired healthy elderly controls with either Alzheimer's disease or suspected non-alzheimer's disease pathophysiology (2015) (0)
Disrupted functional connectivity in autosomal dominant Alzheimer’s disease demonstrates network specificity and precedes brain volume loss: Findings from DIAN (2013) (0)
Subjective cognitive decline and Aβ status are associated with longitudinal episodic memory decline in cognitively normal older adults (2015) (0)
Implementation of the centiloid transformation for F-18 nav4694: Comparison with PiB (2015) (0)
β-AMYLOID AND TAU IMAGING IN OBSTRUCTIVE SLEEP APNOEA: AUSTRALIAN IMAGING BIOMARKERS AND LIFESTYLE-VETERANS STUDY (AIBL-VETS) (2017) (0)
Amyloid imaging in Alzheimer’s disease and dementia with lewy bodies with 11C-PIB-PET (2005) (0)
WHITE MATTER HYPERINTENSITIES IN RELATION TO PATTERNS OF ACCELERATED BRAIN AGING, AD-LIKE ATROPHY AND AMYLOID BURDEN: RESULTS FROM THE ISTAGING CONSORTIUM ON MACHINE LEARNING AND LARGE-SCALE IMAGING ANALYTICS (2019) (0)
Subjective memory complainers in the AIBL cohort: Hypervigilance amongst the worried well, or individuals at increased risk of Alzheimer's disease? (2010) (0)
Recommendations of the International Working Group for the clinical diagnosis of Alzheimer’s disease (2021) (0)
Tau imaging with 18F-MK6240 in Alzheimer’s disease and Traumatic Brain Injury (2019) (0)
EVIDENCE OF AMYLOID ON FLORBETABEN-PET IS ASSOCIATED WITH REDUCED EPISODIC MEMORY 10 YEARS PRIOR: RESULTS FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
Midlife vascular risk and late-life amyloid burden: Data from the Women's Healthy Ageing Project (WHAP) (2013) (0)
AGING: EFFECTS IN SPATIAL LEARNING AND MEMORYAFTER SLEEP DEPRIVATION IN OCTODON DEGUS (2014) (0)
The effect of vascular risk factors on the rate of cognitive change in older adults: Data from the Australian Imaging Biomarkers and Lifestyle (AIBL) flagship study (2013) (0)
Effects of partial volume correction on the analysis of 11C-PiB PET in assessing Alzheimer's disease (2010) (0)
P3-171: Redefining “normal” cognitive performance in ageing using Aβ neuroimaging (2008) (0)
Level of physical activity is associated with hippocampal volume in a subgroup of the AIBL cohort (2012) (0)
AMYLOID PET IS MORE THAN JUST POSITIVE OR NEGATIVE: AMYLOID LEVEL IMPACTS RISK OF CLINICAL PROGRESSION IN NORMAL INDIVIDUALS (2019) (0)
Aβ RELATED MEMORY DECLINE AND HIPPOCAMPAL VOLUME LOSS IN MILD COGNITIVE IMPAIRMENT (2016) (0)
FIXEL-BASED ANALYSIS OF FIBRE TRACT DEGENERATION IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE (2017) (0)
ANTIHYPERTENSIVE TREATMENT AND LONGITUDINAL Aβ MEASURES: RESULTS FROM THE AIBL STUDY OF AGEING (2016) (0)
Plasma levels of homocysteine and red cell folate correlate with neurological composite z-scores in Alzheimer's disease and healthy subjects: The Australian Imaging Biomarker Lifestyle (AIBL) study of aging (2010) (0)
BIOMARKERS FOR VASCULAR CONTRIBUTIONS TO DEMENTIA (2016) (0)
Findings from the first 18-month follow up of the Australian Imaging Biomarkers and Lifestyle (AIBL) cohort (2010) (0)
Automatic 11C PiB SUVR quantification (2013) (0)
A management impact study of VMAT2 PET with [18F]AV-133 in patients with uncertain parkinsonian features: Preliminary findings (2013) (0)
Characterizing patterns of atrophy between cognitively unimpaired healthy elderly controls with either Alzheimer's disease or suspected non-Alzheimer's disease pathophysiology (2015) (0)
COMPARISON OF DIFFERENT TAU PET TRACERS AND THEIR RELATIONSHIP TO AMYLOID (2017) (0)
P1-306: In vivo assessment of β-amyloid deposition: A longitudinal study (2008) (0)
Associations between gonadotropins, testosterone, plasma Aβ and PiB retention in men with subjective memory complaints or mild cognitive impairment (2010) (0)
Preclinical effects of A{beta} deposition on episodic memory and disease progression (2014) (0)
POSTMORTEM HISTOPATHOLOGY-PROOFED EFFICACY AND RELIABILITY OF THE VISUAL ASSESSMENT OF 18F-FLORBETABEN PET SCANS IN THE DETECTION OF CEREBRAL BETA-AMYLOID NEURITIC PLAQUES (2014) (0)
CEREBROVASCULAR DISEASE, ALZHEIMER’S DISEASE BIOMARKERS AND LONGITUDINAL COGNITIVE DECLINE (2016) (0)
Cortical surface projection of PET images from 11C- and 18F-labeled radiotracers without magnetic resonance imaging (2013) (0)
VASCULAR RISK MEASURES AND LONGITUDINAL Aβ ACCUMULATION: RESULTS FROM THE AIBL STUDY OF AGEING (2017) (0)
PARTIAL VOLUME CORRECTION USING EITHER PMOD® OR CAPAIBL® DOES LITTLE TO IMPROVE 18F-AV1451 PET QUANTIFICATION (2018) (0)
SPON1 Is Associated with Amyloid-β and APOE ε4-Related Cognitive Decline in Cognitively Normal Adults (2019) (0)
Mesial temporal tau in amyloid-β-negative cognitively normal older persons (2022) (0)
0297 An Association Between Amyloid Burden and Cognition in Severe Obstructive Sleep Apnea (2018) (0)
SENSITIVITY OF AN ALZHEIMER’S DISEASE COOPERATIVE STUDY: PRECLINICAL ALZHEIMER’S COGNITIVE COMPOSITE (PACC) BASED ON COMPUTERIZED TESTS TO AMYLOID LOAD IN PRECLINICAL AD (2017) (0)
NOVEL STATISTICALLY-DERIVED COMPOSITE MEASURES FOR ASSESSING THE EFFICACY OF DISEASE-MODIFYING THERAPIES IN PRODROMAL AD TRIALS: AN AIPL STUDY (2014) (0)
Cerebral microbleeds, brain beta-amyloid and clinical trajectories: results from the AIBL study of ageing (2013) (0)
A two-year longitudinal assessment of A{beta} deposition in MCI with 18F-Florbetaben (2012) (0)
Elevated PiB precedes dementia in autosomal-dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (0)
PAIRED ASSOCIATE LEARNING DEFICITS ASSOCIATED WITH ELEVATED BETA-AMYLOID IN COGNITIVELY NORMAL OLDER ADULTS (2018) (0)
P2-009: Characterisation of [18]-BF227 binding to α-synuclein (2008) (0)
Cingulate cortex reduction in muscarinic receptors in mild Alzheimer's disease demonstrated with I-123 iodo-dexetimide neuroreceptor spect (2000) (0)
The AIBL study group AIBL Biomarker Stream (2018) (0)
An update on an AIBL blood-based biomarker panel for the prediction of Aβ burden (2012) (0)
TAU, Aβ-AMYLOID, AND COGNITIVE FUNCTION FOLLOWING SERVICE-RELATED TRAUMATIC BRAIN INJURY IN VIETNAM WAR VETERANS (2017) (0)
THE HERITABILITY OF AMYLOID DEPOSITION IN THE BRAINS OF OLDER PEOPLE: THE OLDER AUSTRALIAN TWINS STUDY (2017) (0)
P2-371 Nicotinic receptor upregulation and the cognitive effects of galantamine in Alzheimer’s disease: A human in vivo study using [18F]F-A-85380 PET (2006) (0)
Differential associations of slow wave sleep and amyloid burden with cognitive impairment in obstructive sleep apnoea: a pet imaging study (2019) (0)
β-Amyloid and Tau Imaging in Chronic Traumatic Brain Injury (2022) (0)
Cross-sectional cerebral volumetric differences and associations with estimated time to age-at-onset in familial Alzheimer's disease: Findings from the DIAN study (2012) (0)
Comparing the longitudinal progression of CSF biomarkers with PET Amyloid biomarkers for Alzheimer’s disease (2022) (0)
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimerâ€TMs disease (2019) (0)
HIGHER Aβ BURDEN IN HEALTHY APOE-E4 CARRIERS IS ASSOCIATED WITH SUBJECTIVE MEMORY COMPLAINTS: RESULTS FROM THE FLUTEMETAMOL AND PIB AIPL COHORTS (2014) (0)
Greater rate of atrophy in elderly with high versus low Aβ deposition (2011) (0)
Discordant low amyloid‐β PET and high neocortical tau PET retention (2021) (0)
TAU, Aβ-AMYLOID, AND COGNITIVE FUNCTION FOLLOWING SERVICE-RELATED TRAUMATIC BRAIN INJURY IN VIETNAM WAR VETERANS (2017) (0)
Imaging in familial dementias (2009) (0)
THE HERITABILITY OF AMYLOID DEPOSITION AND ITS SHARED GENETIC BASIS WITH SMALL VESSEL DISEASE IN THE BRAINS OF OLDER PEOPLE (2019) (0)
The consequences of Aβ deposition in aging and Alzheimer's disease: results from 366 elderly subjects (2011) (0)
Identification of concordant plasma lipid signatures in Alzheimer’s disease: Validation between two independent studies of Alzheimer’s disease (2020) (0)
Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies (2014) (0)
Implementation and validation of a method for automated quantification of [18F]flutemetamol imaging data (2012) (0)
TAU, Aβ-AMYLOID, BRAIN STRUCTURE AND COGNITIVE FUNCTION FOLLOWING SERVICE-RELATED TRAUMATIC BRAIN INJURY IN AUSTRALIAN VIETNAM WAR VETERANS (2018) (0)
P2-271 OPTIMAL REFERENCE REGION TO MEASURE LONGITUDINAL AMYLOID-BETACHANGEWITH 18F-FLORBETABEN PET (2019) (0)
O 104-06 CORRELATION OF MEMORY DYSFUNCTION AND AMYLOID BURDEN IN MILD COGNITIVE IMPAIRMENT (2007) (0)
Web-based automated PET and MR quantification (2015) (0)
MK-6240-PET NEUROFIBRILLARY TANGLE PATTERN SUBTYPES ARE ASSOCIATED WITH DISTINCT MEMORY AND COGNITIVE PERFORMANCE (2019) (0)
Plasma p217+tau concordance with 18F‐NAV4694 beta‐amyloid and 18F‐MK6240 tau PET in mild Alzheimer’s disease and cognitively unimpaired participants in the AIBL/ADNeT cohort (2021) (0)
18F-AV1451 TAU QUANTIFICATION WITHOUT MRI (2017) (0)
Gender differences in the relationship between Aβ burden and memory (2010) (0)
316 - Lewy Body Study: An Australian longitudinal biomarker study of dementia with Lewy bodies (2020) (0)
COMPARISON OF EARLY DYNAMIC AMYLOID AND TAU-PET SCANS TO 18F-FDG-PET IMAGE (2016) (0)
A voxel-based morphometry study of volumetric MRI in familial Alzheimer's disease (2012) (0)
EFFECTS OF AB AND BDNF VAL66MET ON EPISODIC MEMORY, HIPPOCAMPAL VOLUME AND SERUM BDNF IN PRECLINICAL ALZHEIMER’S DISEASE (2016) (0)
31. Cost of after-hours myocardial perfusion imaging for acute chest pain diagnosis (2001) (0)
IC-03-03: The Australian Biomarker, Imaging and Lifestyle Study: Preliminary PIB results (2008) (0)
Investigating the impact of scatter correction on Centiloid (2021) (0)
18F-AV1451 TAU QUANTIFICATION WITHOUT MRI (2017) (0)
Cognitive assessments as estimators of neocortical beta-amyloid burden in the AIBL cohort (2012) (0)
PIB-PET CENTILOID QUANTIFICATION USING CAPAIBL (2016) (0)
Centiloid harmonisation strategies across longitudinal studies: Evaluation on AIBL, ADNI and OASIS3 (2021) (0)
In vitro characterization of [F-18]-florbetaben, an A beta imaging radiotracer (2012) (0)
Automatic 11C PiB SUVR quantification (2013) (0)
Amyloid-β and its relevance to the detection of Alzheimer's disease in blood plasma: Findings from the first phase of the Australian Imaging, Biomarker and Lifestyle (AIBL) flagship study of ageing (2009) (0)
The effects of mesial temporal tau in Ab‐negative cognitively normal older adults (2020) (0)
Relation between rates of Aβ deposition, APOE genotype and cognition: Results from a 3- to 5-year longitudinal study (2012) (0)
APOE and cognitive dysfunction in Alzheimer's dementia and mild cognitive impairment (2012) (0)
QUALITATIVE THEMATIC ANALYSIS OF SUBJECTIVE MEMORY COMPLAINTS IN THE HEALTHY ELDERLY AND INDIVIDUALS WITH MCI (2014) (0)
P3-462 CONSIDERATION OF PRECLINICAL AD FROM THE PERSPECTIVE OF NORMAL AGING: AMYLOID-b RELATED CHANGES IN FLUID AND CRYSTALLIZED INTELLIGENCE IN A ROBUST SAMPLEOF HEALTHY OLDER ADULTS (2017) (0)
Baseline and follow-up neuroimaging results from the Australian imaging, biomarker, and lifestyle flagship study of aging (AIBL) (2010) (0)
Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease (2022) (0)
Alzheimer’s disease specific MRI brain regions are differentially associated with accelerated decline as defined using sigmoidal cognitive turning point methodology in amyloid‐positive AIBL participants (2022) (0)
Potential use of cogstate battery to monitor adverse events in individuals taking part in clinical trials of anti-amyloid drugs (2015) (0)
In vivo detection of tau protein deposits in Alzheimer's disease using 18F-labeled 2-phenylquinoline derivatives (2013) (0)
Plasma Aβ biomarker associated with cognitive decline in preclinical Alzheimer’s disease (2020) (0)
Analysis of Peripheral Blood Biomarkers: Towards the Early Diagnosis Alzheimer's Disease (2010) (0)
HEALTHY ADULTS WITH AMYLOID-RELATED MEMORY DECLINE REPORT NO CONCOMITANT DECLINE IN SUBJECTIVE REPORTS OF THEIR MEMORY IMPAIRMENT (2014) (0)
Blood Borne Aβ Dimer Correlates With Clinical Markers of Alzheimer's Disease (2009) (0)
The AIBL study: Baseline data from a multicenter, prospective longitudinal study of ageing in 1,100 volunteers (2009) (0)
Greater rate of atrophy in elderly with high versus low Aβ deposition (2011) (0)
AUTOMATED REPORTING OF AMYLOID PET QUANTIFICATION ON BRAIN SURFACE THROUGH A WEB INTERFACE (2014) (0)
CORRECTING FOR PET SCANNER CHANGES IN LONGITUDINAL STUDIES (2019) (0)
53. Relationship of clinical symptoms to incidental abnormal joint uptake on whole-body 99Tcm-MDP bone scans in a hospital outpatient population (2001) (0)
MIDLIFE VASCULAR RISK, APOLIPOPROTEIN E-E4, AND AMYLOID STATUS 20 YEARS LATER: RESULTS FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
A return to clinical skills in the early diagnosis of Alzheimer's disease (2012) (0)
PIB PET CENTILOID QUANTIFICATION USING CAPAIBL (2016) (0)
A MASS SPECTROMETRY-BASED DISCOVERY AND REPLICATION OF A MULTI-ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY (2017) (0)
Lipidomic signatures for APOE genotypes provides new insights about mechanisms of resilience in Alzheimer’s disease (2021) (0)
THE IMPACT OF APOE ε4 CARRIAGE ON Aβ-AMYLOID DEPOSITION IN AIBL (2017) (0)
P3-620: Increased protein and fibre intake is associated with higher performance in the ABIL PACC score in cognitively normal adults: Australian imaging, biomarkers and lifestyle (ABIL) study (2006) (0)
Understanding the impact of PET amyloid cutpoints on prognostic modelling for cognitively normal individuals (2022) (0)
Quantitative thresholds for 18 F‐florbetaben PET for the detection of low amyloid load: Neuroimaging / Optimal neuroimaging measures for early detection (2020) (0)
TAU AND Aβ-AMYLOID IMAGING IN NIEMANN-PICK TYPE C (2017) (0)
TAU IMAGING IN ALZHEIMER’S DISEASE WITH [F-18]-MK6240, A SECOND GENERATION SELECTIVE TAU TRACER (2018) (0)
Investigating Alzheimer's disease in the blood cellular fraction (2011) (0)
32. Optimal interpretation of resting myocardial perfusion studies for acute chest pain assessment: supine, prone, gated, CEqual or all of the above? (2001) (0)
COMPARISON OF THE NATURAL HISTORY OF NEOCORTICAL Aβ-AMYLOID, HIPPOCAMPAL VOLUME AND PACC IN SPORADIC AD (2018) (0)
FDG metabolism in the DIAN study of autosomal dominant Alzheimer's disease (2012) (0)
Investigating a new neocortical mask for Centiloid quantification (2022) (0)
PET tau imaging in Alzheimer's disease using novel 18F-labeled 2-phenylquinoline derivatives (2013) (0)
JAMA Paper supplement (2015) (0)
Combining white matter density and atrophy information to improve the characterization of axonal loss in Alzheimer's disease (2013) (0)
AUTOMATED REPORTING OF AMYLOID PET QUANTIFICATION ON BRAIN SURFACE THROUGH A WEB INTERFACE (2014) (0)
Change in cognition over 36 months in relation to blood biomarkers (2013) (0)
GENETIC VARIATION WITHIN GENES OF THE SPHINGOLIPID METABOLISM PATHWAY AND THEIR ASSOCIATION WITH ALZHEIMER'S DISEASE RISK AND RELATED PHENOTYPES (2014) (0)
Basal forebrain atrophy and tau pathology are correlated in prodromal AD (2020) (0)
P3-469 FREE AND CUED SELECTIVE REMINDING TEST PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE IN PEOPLE WITH MILD COGNITIVE IMPAIRMENT (2018) (0)
Comparison of PiB and FDG in the differential diagnosis of Alzheimer's disease (2008) (0)
Imaging and cognitive biomarkers as predictors of progression to Alzheimer'S Disease (2012) (0)
Plasma pTau181/Aβ42 identifies cognitive change earlier than CSF pTau181/Ab42 (2022) (0)
P2-092: Prevalence of Aβ positive 11C-PiB PET studies in healthy elderly subjects parallels neuropathology findings (2008) (0)
Association of plasma Amyloid Beta peptides with blood pressure in the elderly (2011) (0)
MK-6240-PET NEUROFIBRILLARY TANGLE PATTERN SUBTYPES ARE ASSOCIATED WITH DISTINCT MEMORY AND COGNITIVE PERFORMANCE (2019) (0)
Correlation between white matter hyperintensities in MRI-FLAIR and 11C-PiB PET retention: A new potential for early identification of disease (2009) (0)
THE CAPTAINS STUDY: STANDARDIZING VISUAL INTERPRETATION STRATEGIES FOR AMYLOID PET TRACERS (2019) (0)
[P4–254]: WITHDRAWN (2017) (0)
Plasma p‐tau181/Aβ1‐42 ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ1‐42 and future cognitive decline (2022) (0)
ASSESSING GLOBAL AND REGIONAL Aβ-AMYLOID DEPOSITION IN THE BRAIN WITH MULTIPLE Aβ-TRACERS USING THE CENTILOID SCALE (2019) (0)
APOE GENOTYPE-DEPENDENT EFFECTS OF DIET AND PHYSICAL ACTIVITY ON COGNITION AND ALZHEIMER'S-RELATED PATHOLOGY: DATA FROM THE AIPL STUDY OF AGEING (2014) (0)
Management impact of FDG-PET in a specialist memory disorders clinic (2008) (0)
Can Brain SPECT Be Used to Cost-effectively Triage Which Patients Require PET for the Investigation of Dementia? (2010) (0)
P4-176 ACTIVITY OF P-GLYCOPROTEIN, AN ABC EFFLUX TRANSPORTER AT THE BLOOD-BRAIN BARRIER, IS COMPROMISED IN ALZHEIMER’S DISEASE (2019) (0)
Brain and hippocampal rates of atrophy in familial Alzheimer's disease mutation carriers: Preliminary findings from the DIAN study (2012) (0)
DIAGNOSTIC AND PROGNOSTIC POWER OF FLUID AND NEUROIMAGING MARKERS OF PATHOLOGY AND NEURODEGENERATION: THE ALZHEIMER'S IMAGING, BIOMARKERS, AND LIFESTYLE (AIBL) STUDY OF AGEING EXPERIENCE (2017) (0)
No association between presence of carotid disease and 11C-PiB-PET in acute stroke patients (2011) (0)
AIBL ACTIVE: A randomized controlled trial of physical activity to delay the progression of white matter hyperintensities on MRI in older adults at risk of cognitive decline (2012) (0)
Using imputation to harmonize longitudinal measures of cognition across two large cohorts: AIBL and ADNI (2020) (0)
PET imaging of amyloid burden and cognitive assessment for the reliable discrimination between healthy aging, subjective memory impairment and mild cognitive impairment (2012) (0)
MODERATE CONSUMPTION OF ALCOHOL MODIFIES THE RISK OF ALZHEIMER’S DISEASE AND IS ASSOCIATED WITH LOWER LEVELS OF CORTISOL (2016) (0)
PARTICIPANTS WHO REFUSE PET SCAN HAD SIGNIFICANTLY LOWER EPISODIC MEMORY THAN THOSE WHO CONSENTED TO SCAN: DATA FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
Quantitative thresholds for 18F‐florbetaben PET for the detection of low amyloid load (2020) (0)
Brain and hippocampal rates of atrophy in familial Alzheimer's disease mutation carriers: Preliminary findings from the DIAN study (2012) (0)
Association of BMI and change in BMI with cognitive function, change in cognitive function and conversion to Alzheimer's disease (2013) (0)
Leukocyte Surface Biomarkers Implicate Deficits of Innate Immunity in Late‐onset Alzheimer’s Disease (2022) (0)
Improved centiloid robustness using non‐negative matrix factorization (2020) (0)
Visual and semiquantitative validation of early and late Aβ imaging approaches using 18F-NAV4694 (2013) (0)
18F-AV-133 VMAT2 Imaging in the Differential Diagnosis of Dementia With Lewy Bodies from Alzheimer's Disease (2010) (0)
The relationship between objective physical activity and change in cognitive function. (2023) (0)
The association between mesial temporal tau with age, cognition and neocortical tau in Aβ cognitively unimpaired individuals using MK‐6240 (2020) (0)
Author Correction: Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer’s disease (2022) (0)
83. 67gallium citrate outperforms 99tcm-sestamibi in evaluating lymphoma patients (2000) (0)
CHAPTER 14 – Single-photon-emission Computed Tomography in Epilepsy (2005) (0)
Those with a family history of dementia were less likely to opt for an amyloid brain scan - Data from the Women’s Healthy Ageing Project (2014) (0)
30. Retrospective comparison of ejection fraction results achieved by radionuclide ventriculography and myocardial perfusion imaging (2001) (0)
EVIDENCE OF AMYLOID ON FLORBETABEN-PET IS ASSOCIATED WITH REDUCED EPISODIC MEMORY 10 YEARS PRIOR: RESULTS FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
IC-P3-208: In vivo characterization of 18F-BAY94-9172: A novel β-amyloid PET ligand for the diagnosis of Alzheimer's disease (2008) (0)
PARTICIPANTS WITH A POSITIVE AMYLOID SCAN IN THE WOMEN’S HEALTHY AGEING PROJECT HAD SIGNIFICANTLY WORSE EPISODIC MEMORY THAN THOSE WITH A NEGATIVE SCAN (2014) (0)
Unpacking cognitive composites: A longitudinal analysis (2021) (0)
WHITE MATTER HYPERINTENSITIES IN RELATION TO PATTERNS OF ACCELERATED BRAIN AGING, AD-LIKE ATROPHY AND AMYLOID BURDEN: RESULTS FROM THE ISTAGING CONSORTIUM ON MACHINE LEARNING AND LARGE-SCALE IMAGING ANALYTICS (2019) (0)
Decreases in cerebral blood flow are associated with Aβ status in preclinical Alzheimer’s disease (2015) (0)
18F-florbetaben Aβ imaging in mild cognitive impairment (2013) (0)
COMORBIDITY OF CEREBROVASCULAR DISEASE AND AMYLOID-β AND ITS INFLUENCE ON RATES OF COGNITIVE DECLINE AND NEURODEGENERATION (2018) (0)
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [ 18 F]flutemetamol PET images: Neuroimaging / Optimal neuroimaging measures for early detection (2020) (0)
A simple test of episodic memory predicts conversion to disease (MCI/AD) aÃƒÆ’Ã†â€™ÃƒÂ¢Ã¢â€šÂ¬Ã…Â¡ÃƒÆ’Ã¢â'¬Å¡Ãƒâ€šÃ'Â decade later: data from the women's healthy ageing project (WHAP) (2014) (0)
P-032 Differentiation between Alzheimer’s disease patients and healthy controls is not possible with 2-[18F]F-A-85380 pet imaging of nicotinic receptors (2007) (0)
Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease. (2022) (0)
Differential associations of modifiable and non‐modifiable dementia risk factors with memory decline and hippocampal volume loss in Aβ‐ and Aβ+ cognitively normal older adults (2021) (0)
SELF-REPORTED PHYSICAL ACTIVITY IS ASSOCIATED WITH TAU BURDEN AS MEASURED BY PET (2017) (0)
PRECLINICAL ALZHEIMER’S DISEASE IS ASSOCIATED WITH LEARNING IMPAIRMENTS OVER SIX DAYS: RESULTS FROM THE ONLINE REPEATED COGNITIVE ASSESSMENT (ORCA) STUDY (2018) (0)
The determination of specificity of PET and SPECT brain scans using a quantitative normal database approach (2011) (0)
IMPACT ON COGNITION IN PERSONS WITH NORMAL COGNITION, MCI, AND DEMENTIA (2014) (0)
IL-10 AND IL-12/23P40 ARE JOINTLY ASSOCIATED AS PREDICTORS OF Aβ-AMYLOID LOAD IN A BROADER BLOOD-BASED BIOMARKER PANEL (2017) (0)
P2-054: Pattern of Aβ deposition in familial Alzheimer's disease is not related to mutation type or cognitive status (2008) (0)
A SIMPLE TEST OF EPISODIC MEMORY PREDICTS CONVERSION TO DISEASE (MCI/AD) A DECADE LATER: DATA FROM THE WOMEN’S HEALTHY AGEING PROJECT (WHAP) (2014) (0)
Automatic image analysis of AV133 PET images (2012) (0)
PARTIAL VOLUME CORRECTION USING EITHER PMOD (cid:1) OR CAPAIBL (cid:1) DOES (2018) (0)
REPORTED EPISODES OF CONFUSION IN HEALTHY PARTICIPANTS HAVE A RELATIONSHIP WITH CEREBRAL AMYLOID LOAD: DATA FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
PERIPHERAL INFLAMMATORY BURDEN BIOMARKERS MODULATE THE RISK FOR ALZHEIMER’S DISEASE THROUGH KEY AD-RELATED SNPS (2018) (0)
INCREASED CEREBRAL BLOOD FLOW WITH INCREASED AMYLOID BURDEN IN PRECLINICAL AD (2018) (0)
Incidence and associations of lobar microbleeds: Results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) (2012) (0)
NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN (2014) (0)
LONGITUDINAL EVALUATION OF THE NATURAL HISTORY OF Aβ IN PLASMA AND BRAIN (2019) (0)
Episodic memory decline is associated with cortical amyloid accumulation in healthy community-dwelling, non demented older adults (2011) (0)
BRAIN BETA-AMYLOID, VASCULAR FACTORS, AND COGNITION: 54-MONTH FOLLOWUP RESULTS FROM THE AIPL STUDY (2014) (0)
P1-277: Examining the regional specificity between Aβ burden and cognition (2008) (0)
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol PET images (2020) (0)
P1–148: Withdrawn (2013) (0)
Characterisation of Pittsburgh Compound-B (PIB) binding to white matter (2007) (0)
The management impact of [18F]AV-133 VMAT2 PET in atypical Parkinson’s disease (2014) (0)
75. Reduced muscarinic receptors in the cingulate cortex in mild Alzheimerʼs disease demonstrated with 123I iodo-dexetamide SPET (2000) (0)
CONVERSION OF AMYLOID QUANTITATION WITH FLORBETAPIR SUVR TO THE CENTILOID SCALE (2016) (0)
1 NIAAA Research Framework : Towards a Biological Definition of Alzheimer ’ s Disease 1 2 draft 11-2 7-17 3 4 (2017) (0)
Avoiding methodological bias in studies of amyloid imaging results disclosure (2019) (0)
Rates of hippocampal atrophy are associated with increased PiB-PET amyloid load in elderly controls (2012) (0)
Disrupted functional connectivity in autosomal dominant Alzheimer’s disease demonstrates network specificity and precedes brain volume loss: Findings from the Dominantly Inherited Alzheimer Network (2013) (0)
EFFECTS OF MAPT OVER BRAIN GREY MATTER ATROPHY IN THE AIBL COHORT (2016) (0)
IN VIVO ASSESSMENT OF MARKERS OF ALZHEIMER’S DISEASE PATHOLOGY IN VIETNAM WAR VETERANS WITH CHRONIC POST-TRAUMATIC STRESS DISORDER (2016) (0)
CARDIOVASCULAR RISK FACTORS MODULATE ALZHEIMER’S DISEASE RISK VIA SNPS IN THE CYP11B2, PPAP2B AND APP GENES (2018) (0)
Correlation of memory decline in “healthy” community volunteers with amyloid-PET imaging (2010) (0)
Rates of hippocampal atrophy are associated with increased PiB-PET amyloid load in elderly controls (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Christopher Cleon Rowe?

Christopher Cleon Rowe is affiliated with the following schools:

Christopher Cleon Rowe's Academic­Influence.com Rankings

Christopher Cleon Rowe's Degrees

Why Is Christopher Cleon Rowe Influential?

Christopher Cleon Rowe's Published Works

Published Works

What Schools Are Affiliated With Christopher Cleon Rowe?

Christopher Cleon Rowe's AcademicInfluence.com Rankings